New spiro-indeno[1,2-b]quinoxalines clubbed with benzimidazole scaffold as CDK2 inhibitors for halting non-small cell lung cancer; stereoselective synthesis, molecular dynamics and structural insights
Barakat, A., Alshahrani, S., Al-Majid, A. M., Alamary, A. S., Haukka, M., Abu-Serie Marwa, M., Domingo, L. R., Ashraf, S., Ul-Haq, Z., Nafie, M. S., & Teleb, M. (2023). New spiro-indeno[1,2-b]quinoxalines clubbed with benzimidazole scaffold as CDK2 inhibitors for halting non-small cell lung cancer; stereoselective synthesis, molecular dynamics and structural insights. Journal of Enzyme Inhibition and Medicinal Chemistry, 38, Article 1. https://doi.org/10.1080/14756366.2023.2281260
Julkaistu sarjassa
Journal of Enzyme Inhibition and Medicinal ChemistryTekijät
Päivämäärä
2023Oppiaine
Epäorgaaninen ja analyyttinen kemiaEpäorgaaninen kemiaInorganic and Analytical ChemistryInorganic ChemistryTekijänoikeudet
© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis
Group
Despite the crucial role of CDK2 in tumorigenesis, few inhibitors reached clinical trials for managing lung cancer, the leading cause of cancer death. Herein, we report combinatorial stereoselective synthesis of rationally designed spiroindeno[1,2-b]quinoxaline-based CDK2 inhibitors for NSCLC therapy. The design relied on merging pharmacophoric motifs and biomimetic scaffold hopping into this privileged skeleton via cost‐effective one-pot multicomponent [3 + 2] cycloaddition reaction. Absolute configuration was assigned by single crystal x-ray diffraction analysis and reaction mechanism was studied by Molecular Electron Density Theory. Initial MTT screening of the series against A549 cells and normal lung fibroblasts Wi-38 elected 6b as the study hit regarding potency (IC50 = 54 nM) and safety (SI = 6.64). In vitro CDK2 inhibition assay revealed that 6b (IC50 = 177 nM) was comparable to roscovitine (IC50 = 141 nM). Docking and molecular dynamic simulations suggested that 6b was stabilised into CDK2 cavity by hydrophobic interactions with key aminoacids.
...
Julkaisija
Informa HealthcareISSN Hae Julkaisufoorumista
1475-6366Asiasanat
Julkaisu tutkimustietojärjestelmässä
https://converis.jyu.fi/converis/portal/detail/Publication/194771001
Metadata
Näytä kaikki kuvailutiedotKokoelmat
Lisätietoja rahoituksesta
The authors extend their appreciation to the Deputyship for Research and Innovation, “Ministry of Education” in Saudi Arabia for funding this research work through the project number IFK-SUOR3–128-3, and project number PID2019-110776GB-I00 (AEI/FEDER, UE), Ministerio de Ciencias, Innovación y Universidades of the Spanish Government.Lisenssi
Samankaltainen aineisto
Näytetään aineistoja, joilla on samankaltainen nimeke tai asiasanat.
-
Synthesis of Enaminones-Based Benzo[d]imidazole Scaffold : Characterization and Molecular Insight Structure
Alshahrani, Saeed; Soliman, Saied M.; Alamary, Abdullah Saleh; Al-Majid, Abdullah Mohammed; Haukka, Matti; Yousuf, Sammer; Barakat, Assem (MDPI AG, 2020)(E)-1-(1H-Benzo[d]imidazol-2-yl)-3-(dimethylamino)prop-2-en-1-one 2 was synthesized by one-pot synthesis protocol of 2-acetyl benzo[d]imidazole with dimethylformamide dimethylacetal (DMF-DMA) in xylene at 140 °C for 8 h. ... -
Discovery of Potent Indolyl-Hydrazones as Kinase Inhibitors for Breast Cancer : Synthesis, X-ray Single-Crystal Analysis, and In Vitro and In Vivo Anti-Cancer Activity Evaluation
Salama, Eid E.; Youssef, Mohamed F.; Aboelmagd, Ahmed; Boraei, Ahmed T. A.; Nafie, Mohamed S.; Haukka, Matti; Barakat, Assem; Sarhan, Ahmed A. M. (MDPI AG, 2023)According to data provided by the World Health Organization (WHO), a total of 2.3 million women across the globe received a diagnosis of breast cancer in the year 2020, and among these cases, 685,000 resulted in fatalities. ... -
Exploring pyrrolidinyl-spirooxindole natural products as promising platforms for the synthesis of novel spirooxindoles as EGFR/CDK2 inhibitors for halting breast cancer cells
Nafie, Mohamed S.; Al-Majid, Abdullah Mohammed; Ali, M.; Alayyaf, Abdulmajeed Abdullah; Haukka, Matti; Ashraf, Sajda; Ul-Haq, Zaheer; El-Faham, Ayman; Barakat, Assem (Frontiers Media, 2024)Cancer represents a global challenge, and the pursuit of developing new cancer treatments that are potent, safe, less prone to drug resistance, and associated with fewer side effects poses a significant challenge in cancer ... -
[3+2] Cycloaddition Reaction for the Stereoselective Synthesis of a New Spirooxindole Compound Grafted Imidazo[2,1-b]thiazole Scaffold : Crystal Structure and Computational Study
Altowyan, Mezna Saleh; Soliman, Saied M.; Haukka, Matti; Al-Shaalan, Nora Hamad; Alkharboush, Aminah A.; Barakat, Assem (MDPI, 2022)A new spirooxindole hybrid engrafted imidazo[2,1-b]thiazole core structure was designed and achieved via [3+2] cycloaddition reaction approach. One multi-component reaction between the ethylene derivative based ... -
The Role of Small-Angle X-Ray Scattering and Molecular Simulations in 3D Structure Elucidation of a DNA Aptamer Against Lung Cancer
Morozov, Dmitry; Mironov, Vladimir; Moryachkov, Roman V.; Shchugoreva, Irina A.; Artyushenko, Polina V.; Zamay, Galina S.; Kolovskaya, Olga S.; Zamay, Tatiana N.; Krat, Alexey V.; Molodenskiy, Dmitry S.; Zabluda, Vladimir N.; Veprintsev, Dmitry V.; Sokolov, Alexey E.; Zukov, Ruslan A.; Berezovski, Maxim V.; Tomilin, Felix N.; Fedorov, Dmitri G.; Alexeev, Yuri; Kichkailo, Anna S. (Elsevier, 2021)Aptamers are short, single-stranded DNA or RNA oligonucleotide molecules that function as synthetic analogs of antibodies and bind to a target molecule with high specificity. Aptamer affinity entirely depends on its tertiary ...
Ellei toisin mainittu, julkisesti saatavilla olevia JYX-metatietoja (poislukien tiivistelmät) saa vapaasti uudelleenkäyttää CC0-lisenssillä.